Long-term risks of chemotherapy

Chemotherapy can generate new cancerous growths and may carry significant cardiovascular risks.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Current treatment regimes for many cancers are so successful that patients are surviving for much longer than initially envisaged. This presents a unique set of problems as the mutagenic effects of their chemotherapy can lead to the long-term development of a second malignancy, but the molecular interactions underlying these observations remain unclear. In February Cancer Cell, Asaf Hellman and colleagues from The Hebrew University, Jerusalem, Israel identify a mechanism by which some chemotherapy drugs create the conditions that can generate new cancerous growths.

Amplification of drug-selected genes in rodent cells is driven by recurrent breaks within chromosomal common fragile sites (CFSs), via the breakage-fusion-bridge (BFB) mechanism. Hellman et al. observed that the same mechanism is involved in the intrachromosomal amplification of the MET oncogene in a human gastric carcinoma. This suggested that in vivo induction of CFSs by chemotherapeutic drugs might play an important role in human oncogenesis (Cancer Cell ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Tudor Toma

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours